Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Cost of Revenue: 2022-2024

Historic Cost of Revenue for Amylyx Pharmaceuticals (AMLX) over the last 3 years, with Dec 2024 value amounting to $6.0 million.

  • Amylyx Pharmaceuticals' Cost of Revenue fell 99.86% to $8,000 in Q2 2024 from the same period last year, while for Jun 2024 it was $20.5 million, marking a year-over-year increase of 48.17%. This contributed to the annual value of $6.0 million for FY2024, which is 76.60% down from last year.
  • According to the latest figures from FY2024, Amylyx Pharmaceuticals' Cost of Revenue is $6.0 million, which was down 76.60% from $25.4 million recorded in FY2023.
  • Amylyx Pharmaceuticals' Cost of Revenue's 5-year high stood at $25.4 million during FY2023, with a 5-year trough of $3.0 million in FY2022.
  • In the last 3 years, Amylyx Pharmaceuticals' Cost of Revenue had a median value of $6.0 million in 2024 and averaged $11.5 million.
  • As far as peak fluctuations go, Amylyx Pharmaceuticals' Cost of Revenue soared by 750.02% in 2023, and later crashed by 76.60% in 2024.
  • Amylyx Pharmaceuticals' Cost of Revenue (Yearly) stood at $3.0 million in 2022, then skyrocketed by 750.02% to $25.4 million in 2023, then tumbled by 76.60% to $6.0 million in 2024.